Open AccessNovel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis
Author(s) -
Leila Gobejishvili,
Walter Rodríguez,
Philip M. Bauer,
Yali Wang,
Chirag Soni,
Todd A. Lydic,
Shirish Barve,
Craig J. McClain,
Claudio Maldonado
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s355796
Subject(s) - rolipram , pharmacology , medicine , adverse effect , phosphodiesterase inhibitor , drug delivery , pharmacokinetics , anesthesia , phosphodiesterase , chemistry , enzyme , biochemistry , organic chemistry
The phosphodiesterase 4 (PDE4) inhibitor, rolipram, has beneficial effects on tissue inflammation, injury and fibrosis, including in the liver. Since rolipram elicits significant CNS side-effects in humans (ie, nausea and emesis), our group developed a fusogenic lipid vesicle (FLV) drug delivery system that targets the liver to avoid adverse events. We evaluated whether this novel liposomal rolipram formulation reduces emesis.